University of California San Francisco Benioff Children's Hospita;
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Verstraete, Sofia
CAMEO, NCT05781152: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Recruiting
4
900
Canada, US
Anti-TNF therapy, Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio
Connecticut Children's Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emory University, Children's Hospital Medical Center, Cincinnati, University of North Carolina, Chapel Hill
Crohn Disease
07/28
07/29
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
PROMOTE IBD, NCT06424769: Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

Recruiting
N/A
900
US
Enhanced Digital Care, Education
University of North Carolina, Chapel Hill, University of Pennsylvania, Centers for Disease Control and Prevention
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
09/28
09/28

Download Options